Arzerra
GSK’s leukaemia drug rejected by NICE
September 16, 2010Sales and Marketing Arzerra, GSK, NHS, NICE
GSK’s leukaemia treatment Arzerra has been rejected by NICE, which says the drug does not represent good value for the …
GSK’s Arzerra conditionally approved in Europe
April 20, 2010Research and Development, Sales and Marketing Arzerra, GSK, leukaemia
GlaxoSmithKline’s orphan cancer treatment Arzerra has been given conditional marketing authorisation in the European Union. Arzerra (ofatumumab) can be used …
In brief: European Medicines Agency news
January 26, 2010Research and Development, Sales and Marketing Arepanrix, Arzerra, EMEA, GSK, Tysabri
GlaxoSmithKline’s influenza vaccine Arepanrix has been granted conditional marketing authorisation in Europe under an emergency fast-track procedure.It is the fourth …
GSK-Genmab blood cancer drug approved in US
November 2, 2009Research and Development, Sales and Marketing Arzerra
GlaxoSmithKline and Philadelphia-based Genmab have received accelerated US approval for their blood cancer drug Arzerra. It is to be used …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
